The "x" in GxP stands for whichever domain applies: GMP (Good Manufacturing Practice) for production, GCP (Good Clinical Practice) for clinical trials, GLP (Good Laboratory Practice) for lab testing, among others. Each has its own detailed regulatory requirements, but they share a common thread: documented, auditable processes with data integrity as a non-negotiable baseline.

For an AI agent operating inside a GxP process, the bar isn't just "does it work," it's whether the system's outputs and decisions are traceable, its data integrity holds up under ALCOA+ scrutiny, and its behavior can be validated and audited the same way a human-run process would be.

Frequently Asked Questions

What's the difference between GMP, GCP, and GLP?

GMP governs manufacturing quality and consistency, GCP governs the ethical and scientific conduct of clinical trials, and GLP governs non-clinical laboratory studies. All three fall under the broader GxP umbrella but apply to different stages of drug development and production.

Why is deploying AI in a GxP environment harder than in a typical back office?

Because the process itself often requires deep pharmaceutical domain knowledge, is undocumented or only partially documented in practice, and any automation has to meet the same validation and audit-trail standard the regulation already requires of the human-run process it's replacing.

Does GxP compliance require every AI decision to be reviewed by a human?

Not necessarily every decision, but the process needs defined escalation points for anything ambiguous or out of specification, and a complete, auditable record of what the system did and why, whether or not a human reviewed each individual case.

How does GxP relate to 21 CFR Part 11?

21 CFR Part 11 is the FDA regulation specifically governing electronic records and electronic signatures within GxP processes, it's the piece that applies most directly when a GxP workflow is digitized or automated rather than run on paper.